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COMPARISON OF EFFICACY OF LUMIRACOXIB 100 MG
OD WITH CELECOXIB 200 MG OD IN THE OVERALL
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PATIENTS WITH OSTEOARTHRITIS OF THE KNEE
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Purpose: To compare the efﬁcacy of lumiracoxib 100 mg od with
placebo and celecoxib 200 mg od in primary knee osteoarthritis
(OA) patients in total population and in age groups <65 and ≥65
Methods: Data from two 13-week, multicenter, randomized,
double-blind, double-dummy, placebo-controlled studies compar-
ing lumiracoxib 100 mg od with celecoxib 200 mg od were
pooled to permit post-hoc combined and subgroup analyses by
age (<65 and ≥65 years) of the prespeciﬁed co-primary end-
points: OA pain intensity in the target knee (0-100 mm VAS),
patient’s global assessment of disease activity (0-100 mm VAS),
and WOMAC™ LK3.1 total score, at study end.
Results: An analysis of the combined data from the two efﬁcacy
studies showed that after 13 weeks of treatment, lumiracoxib 100
mg od (n=1616) was statistically superior to placebo (n=806) for
all three co-primary endpoints (p<0.001). Efﬁcacy of lumiracoxib
100 mg od was similar to celecoxib 200 mg (n=813) for OA
pain intensity in the target knee and WOMAC™ total score and
was statistically signiﬁcantly superior in terms of patient’s global
assessment of disease activity (p=0.044). Of the 3235 patients
in the pooled ITT population, 1894 patients were in the <65
age group [lumiracoxib 100 mg (n=928), placebo (n=477) and
celecoxib 200 mg (n=489)] and 1341 patients were in the ≥65
age group (lumiracoxib 100 mg (n=688), placebo (n=329) and
celecoxib 200 mg (n=324)]. For patients <65 years of age and in
the ≥65 age subgroup, lumiracoxib 100 mg od was statistically
signiﬁcantly superior to placebo and similar to celecoxib for all
three co-primary endpoints (p<0.001) (Table 1).There was no
signiﬁcant treatment by age group interaction for any of the three
co-primary endpoints.
Conclusions: Lumiracoxib provides effective pain relief and im-
provement of functional status in patients with primary knee OA,
with no differences observed in the efﬁcacy endpoints in the two
age groups <65 and ≥65.
Abstract 267 – Table 1. Efﬁcacy of lumiracoxib after 13 weeks of treatment
Efﬁcacy variable Pair wise comparison Total population Age group: <65 Age group: ≥65
Estimated treatment p-value Estimated treatment p-value Estimated treatment p-value
difference (95% CI) difference (95% CI) difference (95% CI)
OA pain Lumiracoxib vs placebo -6.11 (-8.10,-4.12) <0.001 -6.30 (-8.90,-3.69) <0.001 -5.89 (-8.99,-2.79) <0.001
Celecoxib vs placebo -5.20 (-7.50,-2.90) <0.001 -4.36 (-7.34,-1.38) 0.004 -6.45 (-10.07,-2.83) <0.001
Lumiracoxib vs celecoxib -0.91 (-2.90,1.08) 0.368 -1.94 (-4.52,0.65) 0.142 0.56 (-2.56,3.68) 0.725
Patient’s global assessment Lumiracoxib vs placebo -7.28 (-9.24,-5.31) <0.001 -7.50 (-10.07,-4.93) <0.001 -7.03 (-10.08,-3.97) <0.001
of disease activity Celecoxib vs placebo -5.26 (-7.53,-3.00) <0.001 -5.11 (-8.05,-2.18) <0.001 -5.47 (-9.04,-1.89) 0.003
Lumiracoxib vs celecoxib -2.02 (-3.98,-0.06) 0.044 -2.39 (-4.94,0.16) 0.066 -1.56 (-4.63,1.51) 0.320
WOMAC™ total score Lumiracoxib vs placebo -5.64 (-7.04,-4.24) <0.001 -6.00 (-7.83,-4.17) <0.001 -5.17 (-7.34,-3.00) <0.001
Celecoxib vs placebo -4.64 (-6.25,-3.03) <0.001 -4.64 (-6.73,-2.55) <0.001 -4.62 (-7.16,-2.08) <0.001
Lumiracoxib vs celecoxib -1.00 (-2.40,0.39) 0.159 -1.36 (-3.17,0.45) 0.142 -0.55 (-2.74,1.64) 0.622
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PREDICTORS OF DECREASED FUNCTION AND
ACTIVITY LEVEL IN PATIENTS SEEKING TREATMENT
FOR OSTEOARTHRITIS OF THE KNEE
K.K. Briggs, J. Steadman
Steadman Hawkins Research Foundation, Vail, CO
Purpose: Identifying factors associated with decreased function
and decreased activity may help develop early treatment pro-
grams which can decrease the impact of arthritis. The purpose
of this study was to identify determinants of decreased function,
as determined by Lysholm score, and patient activity level, as
determined by Tegner Activity Level, in patients presenting for
evaluation of osteoarthritis of the knee.
Methods: A cohort of patients (n=862, average age = 59 (range
35 to 92); 45% females, 55% males), who were diagnosed with
OA of the knee on initial exam, was studied prospectively. All
patients had complete demographic, subjective and objective
data from the initial exam. Patient symptoms were graded on
a 4-point scale (none, mild, moderate, severe). The dependent
variables were Lysholm score (0-100) for function. This score has
been correlated with the WOMAC score for osteoarthritis. For
activity, the Tegner Activity level(1-10) was used. Univariate and
multivariable analysis were performed to identify determinants.
Results: Prior surgeries were reported in 58% of the knees, and
80% had joint space narrowing on radiographic examination. For
demographic variables, there were no signiﬁcant associations
(p>0.05) between Lysholm and age, or prior surgery. Lysholm
was higher in males (57 vs 47; p=0.001) and Tegner was higher
in males (3.6 vs 2.8; p=0.004). Tegner was signiﬁcantly as-
sociated (P<0.05) with age (rho=-0.15; p=0.001) and gender.
Tegner was also associated with number of prior surgeries, with
knees operated on 2 or more times having signiﬁcantly lower
scores (P<0.05). For objective variables, there was a signiﬁ-
cant difference (p<0.05) in Lysholm for the presence of joint
space narrowing, extension deﬁcits and ﬂexion deﬁcits. Tegner
level was not associated with joint space narrowing, however, it
was associated with extension and ﬂexion deﬁcits. For subjective
symptoms at initial visit, patients with knee stiffness had signiﬁ-
cantly lower Lysholm scores. (p<0.05) Patients reporting severe
stiffness had an average Lysholm score of 26 points less than
those with no stiffness. Multivariate analysis identiﬁed joint space
narrowing and patient reported stiffness as independent predic-
tors of Lysholm (r2=0.41; p<0.05). Independent predictors of
Tegner activity level were age, gender, patient reported stiffness,
ﬂexion deﬁcit, and Lysholm score (r2=0.37; p<0.05).
Conclusions: Determinants of decreased function and de-
creased activity level in patients seeking treatment for os-
teoarthritis of the knee were established. Patient reported stiff-
ness and range of motion deﬁcit were found to be associated
with both decreased activity level and decreased Lysholm score.
These factors may be important in developing early treatment
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programs aimed at improving function and maintaining activity
level in patients with osteoarthritis.
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ENVIRONMENTAL FACTORS AND LIFE SATISFACTION IN
PATIENTS WITH OSTEOARTHRITIS OF KNEE JOINT
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Purpose: To investigate environmental factors reported by pa-
tients with osteoarthritis (OA) of knee joints, and to determine the
relative impact of environmental barriers according to the degree
of OA and an inﬂuence on life satisfaction.
Methods: The subjects were twenty-one patients (mean age
63.5±10.5 years; 4 males, 17 females; mean prevalence pe-
riod 17.8±13.9 years) with OA who met the American Col-
lege of Rheumatology criteria for the classiﬁcation and reporting
of osteoarthritis of the knee. We assessed the clinical sever-
ity by Western Ontario and McMaster University Osteoarthritis
(WOMAC) index and the radiological grade by Kellgren-Lawrence
(KL) scales. We measured the frequency (never, less than
monthly, monthly, weekly, daily) and magnitude (little problem,
big problem) of perceived environmental barriers in 5 domains
which composed of physical/structure, services/assistance, poli-
tics, attitudes/support, and work/school environmental barriers by
the Craig Hospital Inventory of Environmental Factors (CHIEF).
Persistent barriers deﬁned as frequency and magnitude product
scores ≥ 3. The life satisfaction was measured by SF-8 health
survey. We performed comparative analysis of CHIEF subscales
according to the degree of OA.
Results: 1) Perceived environmental barriers in one or more do-
mains were reported in 80% of subjects and persistent barriers
in 35% of subjects. 2) The ADL score of WOMAC index was sig-
niﬁcantly correlated with the score of SF-8 (r=0.61, p=0.004), but
there was no correlated with the subscales of CHIEF (p>0.05).
3) The KL scales were no correlated with the scores of SF-8
(p>0.05). 4) The subscales of CHIEF were signiﬁcant correlated
with the scores of SF-8 (physical/structure r=0.61, p=0.004; ser-
vices/assistance r=0.57, p=0.008; politics r=0.60, p=0.005; atti-
tudes/support r=0.63, p=0.003; work/school r=0.57, p=0.008).
Conclusions:Perceived environmental barriers are highly preva-
lent, and so we suggest that the reduction of environmental bar-
riers may lead to the improvement of quality of life in patients
with knee OA.
This work was supported by the Korea Research Foundation
Grant funded by the Korean Government (MOEHRD) (The Re-
gional Research Universities Program/Biohousing Research In-
stitute)
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PRE-RADIOGRAPHIC MRI FINDINGS ARE ASSOCIATED
WITH ONSET OF KNEE PAIN: THE MOST STUDY
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Birmingham, AL
Purpose: MRI has a greater sensitivity than X-rays to detect
osseous and soft tissue changes that may occur in initial stages
of OA. However, it is uncertain which, if any, MRI ﬁndings in
otherwise normal knees are more common in those that develop
OA. Hence, we examined if MRI abnormalities detected in knees
without any radiographic features of knee OA were associated
with the onset of knee pain within 15 months.
Methods: Subjects were participants in MOST, an observational
study of persons with or at high risk of knee OA. At baseline, sub-
jects were asked about frequent knee symptoms (FKS), deﬁned
as pain on most days of the past month, had weight-bearing PA
(ﬁxed ﬂexion) and lateral knee x-rays, and underwent axial and
sagittal proton density FSE fat suppressed and coronal STIR
MRI (1.0 T OrthOne™ extremity scanner). Knees without FKS at
baseline that developed FKS at the 15 month visit were deﬁned
as cases; control knees were drawn randomly from the same
source population as cases, but without FKS at followup. We
analyzed a subset of case and control knees that did not have
osteophytes or joint space narrowing at baseline (OARSI grade
= 0 in all locations) in the tibio-femoral and patello-femoral joint
(PFJ) using the PA and lateral views respectively. Baseline MRIs
were graded using the WORMS method and feature grades at
each subregion were classiﬁed as ANY and severe (SEV) for
cartilage (ANY >1, SEV=5/6); osteophytes (ANY >0, SEV=4-7);
bone marrow lesions (BML) and cysts (ANY >0, SEV =2,3).
Cases and controls were compared for the presence of ANY and
for presence of SEV features in a) one or more subregion, b)
total number of subregions involved and c) location of subregion
involvement. Logistic GEE models were adjusted for age, gender,
race and BMI.
Results: There were 47 case knees and 198 control knees from
214 participants included in the analysis. Mean age was 60.4
yrs, 64% were female and 85% Caucasian. Among these knees,
structural damage as measured by ANY or SEV lesions was
common: osteophytes- 94% ANY (6% SEV); cartilage 68% ANY
(14% SEV); BML 52% ANY (17% SEV); subchondral cysts 21%
ANY (2% SEV). Of those with FKS at 15 months, the presence of
ANY (p=0.001) and SEV (p=0.002) MRI features of all types was
greater in cases than controls. Compared with controls, cases
had signiﬁcantly more subregions with ANY (p=0.005) osteo-
phytes, ANY (p=0.009) and SEV (p=0.02) BML and ANY cysts
(p=0.039). In contrast, the number of subregions with cartilage
damage did not differ between cases and controls (p>0.1). By
location, there was signﬁcantly (p<0.05) more damage to the
medial patella region (for cartilage, osteophyte, BML and cyst
features) and lateral patella (for BML features) in cases com-
pared with controls. In addition, at the tibial subspinous region
only, the presence of a BML was signiﬁcantly more common in
cases and in a multivariate logistic model, was an independent
predictor of incident FKS adjusting for age, gender, race and BMI
(OR 9.3 (1.9 -44.1)) (Fig. 1).
Figure 1
Conclusions: These ﬁndings suggest that lesions detected by
